Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Madrigal Pharmaceuticals Inc
Long-Term Debt
Madrigal Pharmaceuticals Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
Long-Term Debt
$117.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
38%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Debt
$60.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Debt
$24.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Debt
$56.5B
|
CAGR 3-Years
19%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Debt
$112.8m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-18%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Long-Term Debt
$2.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
31%
|
CAGR 10-Years
19%
|
|
Madrigal Pharmaceuticals Inc
Glance View
In the competitive and complex landscape of pharmaceuticals, Madrigal Pharmaceuticals Inc. has carved a niche for itself by focusing on the development of innovative therapies for metabolic and liver diseases. Founded with the visionary zeal to address unmet medical needs, Madrigal's journey is grounded in its dedication to advancing science and transforming patient care. The company's primary research and development efforts center around addressing non-alcoholic steatohepatitis (NASH), a significant liver condition that lacks approved treatments. With a keen eye on scientific innovation, Madrigal invests heavily in creating solutions for conditions that are not only challenging but also growing in prevalence, thus embodying the dual mission of driving better health outcomes and capturing market opportunities. Madrigal's business model is largely reliant on the successful progression of its lead candidate, resmetirom, through clinical trials and regulatory approval processes. This strategy, typical in the pharmaceutical arena, involves rigorous stages of testing to ensure efficacy and safety, aiming to bring the drug to market where it can address the substantial need. Revenue generation for Madrigal is intrinsically linked to licensing agreements, strategic partnerships, and eventual drug sales post-approval. This approach necessitates significant initial investment and patience, with the expectation of substantial returns contingent upon successful product commercialization. Through this focus, Madrigal advances towards not only improving the therapeutic landscape for liver diseases but also carving out a significant presence in the biotech market.
See Also
What is Madrigal Pharmaceuticals Inc's Long-Term Debt?
Long-Term Debt
117.1m
USD
Based on the financial report for Dec 31, 2024, Madrigal Pharmaceuticals Inc's Long-Term Debt amounts to 117.1m USD.
What is Madrigal Pharmaceuticals Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
38%
Over the last year, the Long-Term Debt growth was 1%.
You don't have any saved screeners yet